SEC-sourced researchBeta

TXG

10x Genomics, Inc.

US markets

Data passport

CIK: 0001770787
Exchange: Nasdaq
Business activity: — · SIC 3826
Financial inputs: 6/6
Filing date: Oct 7, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 8:04 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

TXG · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	618,727,000.0000	Feb 13, 2026
December 2024	610,785,000.0000	Feb 13, 2026
December 2025	642,823,000.0000	Feb 13, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	642,823,000.0000	-43,544,000.0000	136,050,000.0000	1,041,365,000.0000	245,039,000.0000	Feb 13, 2026
December 2024	610,785,000.0000	-182,627,000.0000	6,664,000.0000	918,636,000.0000	208,502,000.0000	Feb 13, 2026
December 2023	618,727,000.0000	-255,099,000.0000	-15,197,000.0000	—	—	Feb 13, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$642.82M	December 2025	Feb 13, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$610.79M	December 2024	Feb 13, 2026	10-K
Net incomeNetIncomeLoss	-$43.54M	December 2025	Feb 13, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	$136.05M	December 2025	Feb 13, 2026	10-K
Total assetsAssets	$1.04B	December 2025	Feb 13, 2026	10-K
Total liabilitiesLiabilities	$245.04M	December 2025	Feb 13, 2026	10-K

New filings

Explore methodology ↗